U.S. Congress legislation · 119th Congress
HB10887: Protecting Consumer Access to Generic Drugs Act of 2026
Status: In committee, October 22, 2026
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
What the bill says
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
From the introduced text, October 22, 2026:
A BILL To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes. SECTION 1. Short title This Act may be cited as the Protecting Consumer Access to Generic Drugs Act of 2026 . SECTION 2. Unlawful agreements (a) Agreements prohibited Subject to subsections (b) and (c), it shall be unlawful for an NDA or BLA holder and a subsequent filer (or for two subsequent filers) to enter into, or carry out, an agreement resolving or settling a covered patent infringement claim on a final or interim basis if under such agreement-- (1) a subsequent filer directly or indirectly receives from such holder (or in the case of such an agreement between two subsequent filers, the other subsequent filer) anything of value, including a license; and (2) the subsequent filer agrees to limit or forego research on, or development, manufacturing, marketing, or sales of, for any period of time, the covered product that is the subject of the application described in subparagraph (A) or (B) of subsection (g)(8). (b) Exclusion It shall not be unlawful under subsection (a) if a party to an agreement described …
Sponsors
- Seth Magaziner (D, HD-002) · primary sponsor
Latest actions
- : Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- : Introduced in House
Subjects: Health
Common questions
- What is HB10887?
- HB10887 is a bill in Congress (119th Congress): Protecting Consumer Access to Generic Drugs Act of 2026.
- What does HB10887 do?
- In its own words: To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
- What is the status of HB10887?
- In committee as of October 22, 2026. Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (October 22, 2026).
- Who sponsored HB10887?
- Seth Magaziner (D, HD-002).
- Where is the official record for HB10887?
- On the Congress website: https://www.congress.gov/bill/119th-congress/house-bill/10887
Source: official Congress record. Tracked by Delilah, AI for legislation across all 50 states and Congress.